LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 90 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2020. The put-call ratio across all filers is 0.05 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $428,594 | -16.3% | 363,215 | 0.0% | 0.00% | – |
Q2 2023 | $512,133 | +400.7% | 363,215 | +432.7% | 0.00% | – |
Q1 2023 | $102,275 | +91.9% | 68,183 | +49.7% | 0.00% | – |
Q4 2022 | $53,288 | +2.5% | 45,545 | 0.0% | 0.00% | – |
Q3 2022 | $52,000 | -27.8% | 45,545 | 0.0% | 0.00% | – |
Q2 2022 | $72,000 | -85.9% | 45,545 | -86.3% | 0.00% | – |
Q1 2022 | $512,000 | -33.8% | 332,406 | +5.4% | 0.00% | – |
Q4 2021 | $773,000 | -2.8% | 315,354 | 0.0% | 0.00% | – |
Q3 2021 | $795,000 | -13.5% | 315,354 | -2.2% | 0.00% | – |
Q2 2021 | $919,000 | +706.1% | 322,361 | +569.3% | 0.00% | – |
Q1 2021 | $114,000 | -2.6% | 48,167 | -27.2% | 0.00% | – |
Q4 2020 | $117,000 | +88.7% | 66,180 | 0.0% | 0.00% | – |
Q3 2020 | $62,000 | +6.9% | 66,180 | 0.0% | 0.00% | – |
Q2 2020 | $58,000 | -70.1% | 66,180 | -71.7% | 0.00% | – |
Q1 2020 | $194,000 | -6.7% | 233,687 | 0.0% | 0.00% | – |
Q4 2019 | $208,000 | -9.6% | 233,687 | 0.0% | 0.00% | – |
Q3 2019 | $230,000 | – | 233,687 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Defender Capital, LLC. | 4,735,990 | $8,335,000 | 3.63% |
BROADWOOD CAPITAL INC | 34,005,379 | $59,849,000 | 3.55% |
Prescott General Partners LLC | 1,851,851 | $3,259,000 | 0.14% |
Strategic Wealth Investment Group, LLC | 66,917 | $118,000 | 0.07% |
Laidlaw Wealth Management LLC | 170,658 | $300,000 | 0.06% |
Humankind Investments LLC | 26,737 | $47,000 | 0.05% |
DAFNA Capital Management LLC | 80,000 | $141,000 | 0.04% |
Beirne Wealth Consulting Services, LLC | 45,000 | $79,000 | 0.04% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 680,839 | $1,198,000 | 0.02% |
Allegheny Financial Group LTD | 20,000 | $35,000 | 0.02% |